Regeneron Pharmaceuticals
REGN
Market cap $60.7B

572.38 USD

-17.10

2.90%

At close Aug 25, 4:00 PM EDT

Pre-market

576.00

+3.62

0.63%

1 day

-2.90%

5 days

-0.51%

1 month

1.65%

3 months

-5.12%

6 months

-20.88%

Year to date

-19.97%

1 year

-52.28%

5 years

-6.24%

10 years

14.70%

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,207

Healthcare Biotechnology

0

Funds holding %

of 7,429 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

36% more call options, than puts

Call options by funds: $860M | Put options by funds: $632M

6% less repeat investments, than reductions

Existing positions increased: 434 | Existing positions reduced: 462

1.35% less ownership

Funds ownership: 85.21% [Q1] → 83.86% (-1.35%) [Q2]

7% less funds holding

Funds holding: 1,270 [Q1] → 1,175 (-95) [Q2]

20% less capital invested

Capital invested by funds: $58.1B [Q1] → $46.7B (-$11.4B) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 15 [Q1] → 12 (-3) [Q2]

32% less first-time investments, than exits

New positions opened: 133 | Existing positions closed: 197

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$580

1%

upside

Avg. target

$719

26%

upside

High target

$850

49%

upside

10 analyst ratings

7 positive

70%

3 neutral

30%

0 negative

0%

Truist Securities Srikripa Devarakonda	42%upside $812	Buy Maintained	11 Aug 2025
BMO Capital Evan David Seigerman	12%upside $640	Outperform Maintained	4 Aug 2025
Morgan Stanley Matthew Harrison	33%upside $761	Overweight Maintained	4 Aug 2025
RBC Capital Brian Abrahams	21%upside $695	Sector Perform Maintained	4 Aug 2025
Guggenheim Yatin Suneja	42%upside $815	Buy Maintained	4 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 31 articles about REGN published over the past 30 days

The Motley Fool

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

Viking Therapeutics (VKTX 1.32%) and Regeneron Pharmaceuticals (REGN -1.45%) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter has declined 17%.

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs

Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is five years and $3.2 billion in the making.

A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs

Zacks Investment Research

FDA Extends Review Period of REGN's Submission for Eylea HD

The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.

FDA Extends Review Period of REGN's Submission for Eylea HD

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications.

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

Zacks Investment Research

Can Eylea HD and Dupixent Profits Revive Regeneron Stock?

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Can Eylea HD and Dupixent Profits Revive Regeneron Stock?

‘Big Short' Michael Burry stock portfolio update

Michael Burry, the legendary “Big Short” investor and founder of Scion Asset Management has revealed a substantial reshuffle in his Q2 2025 holdings, adding heavyweight names across healthcare, retail, biotech, and e-commerce while trimming his largest position.

‘Big Short' Michael Burry stock portfolio update

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity

Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic moves in obesity drugs aim for future growth.

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

On Friday, Regeneron Pharmaceuticals Inc. REGN reported upbeat second-quarter earnings.

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

The Motley Fool

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts

The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts

The Motley Fool

Regeneron (REGN) Q2 EPS Jumps 53%

Regeneron (REGN) Q2 EPS Jumps 53%

Regeneron (REGN) Q2 EPS Jumps 53%

See News Rankings

Charts implemented using Lightweight Charts™